

Engagement Report for Clinical Commissioning Policies

Unique Reference Number	170101P
Policy Title	Gemcitabine and capecitabine following surgery for pancreatic cancer
Lead Commissioner	
Clinical Reference Group	Chemotherapy
Which stakeholders were contacted to be involved in policy development?	<p>A policy working group was established as per NHS England policy, clinical and PPV reps were members of the chemotherapy CRG.</p> <p>All CRG members and registered stakeholders were sent copies of the draft policy documents for comment.</p>
Identify the relevant Royal College or Professional Society to the policy and indicate how they have been involved	<p>All of the relevant Royal Colleges and professional societies have membership on the CRG. These include:</p> <p>British Oncology Pharmacy Association</p> <p>Royal College of Pathologists</p> <p>British Society for Haematology</p> <p>A representative for each group was sent all policy documents and given the opportunity to comment.</p>
Which stakeholders have actually been involved?	CRG members and a response from eight registered stakeholders regarding draft documents
Explain reason if there is any difference from previous question	N/A
Identify any particular stakeholder organisations	N/A

that may be key to the policy development that you have approached that have yet to be engaged. Indicate why?	
How have stakeholders been involved? What engagement methods have been used?	As per policy development process all CRG members and CRG registered stakeholders have been sent draft policy documents for comment.
What has happened or changed as a result of their input?	<p>Based on feedback from the stakeholder consultation the PWG would like to propose that the original policy proposition including both R0 and R1 resections is resubmitted to Clinical Panel. When the policy proposition was first presented to Clinical Panel in April they agreed the policy should proceed to include only R0 resections but this has been strongly refuted by the stakeholder feedback and the Chair of the CRG as the trial data does not support subgroup analysis.</p> <p><i>Postscript – It was agreed to include both R0 and R1 within the policy proposition.</i></p>
How are stakeholders being kept informed of progress with policy development as a result of their input?	Communication will be according to NHS England policy development process.
What level of wider public consultation is recommended by the CRG for the NPOC Board to agree as a result of stakeholder involvement?	Depending on the review of the changes by Clinical Panel the CRG recommends 30 days public consultation based on the level of stakeholder response and the nature of the policy.